APN News

  • Friday, April, 2024| Today's Market | Current Time: 10:42:45
  • Kartavya Healtheon seeking expansion in Disease Management at Dubai and South Africa

    Published on May 22, 2013

    karthavyaMumbai : Kartavya Healtheon, a  pioneer in ‘patient care management’  will soon roll out their chronic disease management services in evolving countries like the UAE and South Africa. The company is also seeking expansion to streamline the benefits of DM services in these countries by enhancing their presence in assisting patients of chronic diseases. They will also provide patient care support programs like counseling, diet and nutrition, disease awareness and medication adherence into disease management hubs.

    In addition to this Kartavya Healtheon is eyeing to enlarge their Disease Management portfolio by providing preventive and self-managed care to patients. This will grow the company’s margin and the needs of primary health care in these countries. Kartavya Healtheon’s CEO Mr. Vikram Srivastava said, “We felt a need as we received many queries that made us to think about it. We see a great potential in these countries as Disease management is gradually picking up pace. We have aimed to make this sector more organized by targeting Africa and middle east. In order to control the viral spread of the chronic illnesses, we at Kartavya Healtheon will soon introduce the concept of self-controlled patient management through subscription based model. In India, by next 1 year we will come out with various programmes for chronic disease which would significantly reduce the healthcare burden cost on patients and provide better outcome of the treatment / therapy”

    Chronic diseases like Cancer, hepatitis B, HIV and diabetes are increasing rapidly across the country. Also, there is a continuous gap in chronic care and lifestyle condition awareness, screening and behavioural modification. We are doing this because access to information and disease awareness is very low and healthcare cost is rising day by day.

    SEE COMMENTS

    Leave a Reply